CGRP-mediated Cancer Pain Mechanisms and Targeted Therapeutic Approaches

Beining TANG; Shihao SHAO; Tao LI; Yun SHA; Jinyuan YANG; Zejing HUANGFU; Xinyu GU; Zhonghui WANG

Article Contents

Article Navigation > Journal of Kunming Medical University > 2026 > Accepted Manuscript

Beining TANG, Shihao SHAO, Tao LI, Yun SHA, Jinyuan YANG, Zejing HUANGFU, Xinyu GU, Zhonghui WANG. CGRP-mediated Cancer Pain Mechanisms and Targeted Therapeutic Approaches[J]. Journal of Kunming Medical University.

Citation:

PDF( 3466 KB)

CGRP-mediated Cancer Pain Mechanisms and Targeted Therapeutic Approaches

1.
Department of Anesthesiology and Surgery
2.
Department of Center for Cancer Biotherapy，The Third Affiliated Hospital of Kunming Medical University，Yunnan Cancer Hospital，Peking University Cancer Hospital Yunnan，Kunming Yunnan 650118，China

Received Date: 2025-12-15

Abstract

Abstract

Calcitonin gene-related peptide （CGRP） exerts a central-peripheral synergistic amplification effect in the development and maintenance of cancer pain. This effect is mediated through the activation of signaling pathways, including NGF and BMP2, leading to increased sensory nerve excitability, the promotion of peripheral and central sensitization, and the formation of a "pain-tumor progression" positive feedback loop with the tumor microenvironment. Preclinical evidence has demonstrated the significant analgesic and anti-tumor potential of CGRP antagonists in models including breast cancer, oral cancer, and pancreatic cancer, among others. Furthermore, CGRP levels are closely correlated with cancer pain intensity, suggesting its potential value as a biomarker and intervention target for targeted cancer pain therapy. This review summarizes the mechanistic roles of CGRP in cancer pain and tumor progression, as well as recent advances in related therapeutic research, and explores future strategies for cancer pain management through targeting the CGRP pathway in combination with existing treatment modalities.
- CGRP,
- Cancer-related pain,
- Tumor microenvironment,
- Targeted therapy,
- Clinical translation

FullText(HTML)

References(86)

References

[1]	Zhang H. Cancer pain management-new therapies[J]. Curr Oncol Rep, 2022, 24(2): 223-226.
[2]	Furlan A D, Sandoval J A, Mailis-Gagnon A, et al. Opioids for chronic noncancer pain: A meta-analysis of effectiveness and side effects[J]. CMAJ, 2006, 174(11): 1589-1594.
[3]	Villars P, Dodd M, West C, et al. Differences in the prevalence and severity of side effects based on type of analgesic prescription in patients with chronic cancer pain[J]. J Pain Symptom Manage, 2007, 33(1): 67-77.
[4]	Paice J A, Ferrell B. The management of cancer pain[J]. CA A Cancer J Clin, 2011, 61(3): 157-182.
[5]	Deng G. Integrative medicine therapies for pain management in cancer patients[J]. Cancer J, 2019, 25(5): 343-348.
[6]	Seybold V S. The role of peptides in central sensitization[J]. Handb Exp Pharmacol, 2009(194): 451-491.
[7]	Cady R J, Glenn J R, Smith K M, et al. Calcitonin gene-related peptide promotes cellular changes in trigeminal neurons and Glia implicated in peripheral and central sensitization[J]. Mol Pain, 2011, 7: 94.
[8]	Sun R Q, Tu Y J, Lawand N B, et al. Calcitonin gene-related peptide receptor activation produces PKA- and PKC-dependent mechanical hyperalgesia and central sensitization[J]. J Neurophysiol, 2004, 92(5): 2859-2866.
[9]	Bloom A P, Jimenez-Andrade J M, Taylor R N, et al. Breast cancer-induced bone remodeling, skeletal pain, and sprouting of sensory nerve fibers[J]. J Pain, 2011, 12(6): 698-711.
[10]	Tu N H, Inoue K, Lewis P K, et al. Calcitonin related polypeptide alpha mediates oral cancer pain[J]. Cells, 2023, 12(13): 1675.
[11]	Han L, Jiang J, Xue M, et al. Sonic hedgehog signaling pathway promotes pancreatic cancer pain via nerve growth factor[J]. Reg Anesth Pain Med, 2020, 45(2): 137-144.
[12]	Mulderry P K, Ghatei M A, Spokes R A, et al. Differential expression of alpha-CGRP and beta-CGRP by primary sensory neurons and enteric autonomic neurons of the rat[J]. Neuroscience, 1988, 25(1): 195-205.
[13]	Russo A F, Nelson C, Roos B A, et al. Differential regulation of the coexpressed calcitonin/alpha-CGRP and beta-CGRP neuroendocrine genes[J]. J Biol Chem, 1988, 263(1): 5-8.
[14]	Poyner D R, Sexton P M, Marshall I, et al. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors[J]. Pharmacol Rev, 2002, 54(2): 233-246.
[15]	Russell F A, King R, Smillie S J, et al. Calcitonin gene-related peptide: Physiology and pathophysiology[J]. Physiol Rev, 2014, 94(4): 1099-1142.
[16]	Russo A F, Hay D L. CGRP physiology, pharmacology, and therapeutic targets: Migraine and beyond[J]. Physiol Rev, 2023, 103(2): 1565-1644.
[17]	Rosenfeld M G, Amara S G, Roos B A, et al. Altered expression of the calcitonin gene associated with RNA polymorphism[J]. Nature, 1981, 290(5801): 63-65.
[18]	Amara S G, Jonas V, Rosenfeld M G, et al. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products[J]. Nature, 1982, 298(5871): 240-244.
[19]	Rosenfeld M G, Mermod J J, Amara S G, et al. Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing[J]. Nature, 1983, 304(5922): 129-135.
[20]	Grunditz T, Ekman R, Håkanson R, et al. Calcitonin gene-related peptide in thyroid nerve fibers and C cells: Effects on thyroid hormone secretion and response to hypercalcemia[J]. Endocrinology, 1986, 119(5): 2313-2324.
[21]	Uddman R, Luts A, Sundler F. Occurrence and distribution of calcitonin gene-related peptide in the mammalian respiratory tract and middle ear[J]. Cell Tissue Res, 1985, 241(3): 551-555.
[22]	Johnson D E, Wobken J D. Calcitonin gene-related peptide immunoreactivity in airway epithelial cells of the human fetus and infant[J]. Cell Tissue Res, 1987, 250(3): 579-583.
[23]	Tsukiji J, Sango K, Udaka N, et al. Long-term induction of beta-CGRP mRNA in rat lungs by allergic inflammation[J]. Life Sci, 2004, 76(2): 163-177.
[24]	Timmermans J P, Scheuermann D W, Barbiers M, et al. Calcitonin gene-related peptide-like immunoreactivity in the human small intestine[J]. Acta Anat, 1992, 143(1): 48-53.
[25]	Kuramoto H, Kondo H, Fujita T. Calcitonin gene-related peptide (CGRP)-like immunoreactivity in scattered chromaffin cells and nerve fibers in the adrenal gland of rats[J]. Cell Tissue Res, 1987, 247(2): 309-315.
[26]	García-Caballero T, Gallego R, Rosón E, et al. Calcitonin gene-related peptide (CGRP) immunoreactivity in the neuroendocrine Merkel cells and nerve fibres of pig and human skin[J]. Histochemistry, 1989, 92(2): 127-132.
[27]	Wang W, Jia L, Wang T, et al. Endogenous calcitonin gene-related peptide protects human alveolar epithelial cells through protein kinase Cepsilon and heat shock protein[J]. J Biol Chem, 2005, 280(21): 20325-20330.
[28]	Linscheid P, Seboek D, Zulewski H, et al. Autocrine/paracrine role of inflammation-mediated calcitonin gene-related peptide and adrenomedullin expression in human adipose tissue[J]. Endocrinology, 2005, 146(6): 2699-2708.
[29]	Timper K, Grisouard J, Radimerski T, et al. Glucose-dependent insulinotropic polypeptide (GIP) induces calcitonin gene-related peptide (CGRP)-I and procalcitonin (Pro-CT) production in human adipocytes[J]. J Clin Endocrinol Metab, 2011, 96(2): E297-E303.
[30]	Hou Q, Barr T, Gee L, et al. Keratinocyte expression of calcitonin gene-related peptide β: Implications for neuropathic and inflammatory pain mechanisms[J]. Pain, 2011, 152(9): 2036-2051.
[31]	Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer[J]. Pharmacol Ther, 2021, 221: 107753.
[32]	Liu Y, Li C, Lu Y, et al. Tumor microenvironment-mediated immune tolerance in development and treatment of gastric cancer[J]. Front Immunol, 2022, 13: 1016817.
[33]	Anderson N M, Simon M C. The tumor microenvironment[J]. Curr Biol, 2020, 30(16): R921-R925.
[34]	Mardelle U, Bretaud N, Daher C, et al. From pain to tumor immunity: Influence of peripheral sensory neurons in cancer[J]. Front Immunol, 2024, 15: 1335387.
[35]	Zhang Y, Lin C, Wang X, et al. Calcitonin gene-related peptide: A promising bridge between cancer development and cancer-associated pain in oral squamous cell carcinoma[J]. Oncol Lett, 2020, 20(5): 253.
[36]	Tajti J, Uddman R, Edvinsson L. Neuropeptide localization in the “migraine generator” region of the human brainstem[J]. Cephalalgia, 2001, 21(2): 96-101.
[37]	van Rossum D, Hanisch U K, Quirion R. Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors[J]. Neurosci Biobehav Rev, 1997, 21(5): 649-678.
[38]	Rees T A, Hendrikse E R, Hay D L, et al. Beyond CGRP: The calcitonin peptide family as targets for migraine and pain[J]. Br J Pharmacol, 2022, 179(3): 381-399.
[39]	Basbaum A I, Bautista D M, Scherrer G, et al. Cellular and molecular mechanisms of pain[J]. Cell, 2009, 139(2): 267-284.
[40]	Willis W D Jr. Dorsal root potentials and dorsal root reflexes: A double-edged sword[J]. Exp Brain Res, 1999, 124(4): 395-421.
[41]	Woolf C J. Central sensitization: Implications for the diagnosis and treatment of pain[J]. Pain, 2011, 152(3 Suppl): S2-S15.
[42]	Iyengar S, Ossipov M H, Johnson K W. The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine[J]. Pain, 2017, 158(4): 543-559.
[43]	Weidner C, Klede M, Rukwied R, et al. Acute effects of substance P and calcitonin gene-related peptide in human skin—a microdialysis study[J]. J Invest Dermatol, 2000, 115(6): 1015-1020.
[44]	Latremoliere A, Woolf C J. Synaptic plasticity and central sensitization: Author reply[J]. J Pain, 2010, 11(8): 801-803.
[45]	Kestell G R, Anderson R L, Clarke J N, et al. Primary afferent neurons containing calcitonin gene-related peptide but not substance P in forepaw skin, dorsal root ganglia, and spinal cord of mice[J]. J Comp Neurol, 2015, 523(17): 2555-2569.
[46]	Latremoliere A, Woolf C J. Central sensitization: A generator of pain hypersensitivity by central neural plasticity[J]. J Pain, 2009, 10(9): 895-926.
[47]	Woolf C J, Thompson S W N. The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states[J]. Pain, 1991, 44(3): 293-299.
[48]	Seidel M F, Wise B L, Lane N E. Nerve growth factor: An update on the science and therapy[J]. Osteoarthritis Cartilage, 2013, 21(9): 1223-1228.
[49]	Iyengar S, Johnson K W, Ossipov M H, et al. CGRP and the trigeminal system in migraine[J]. Headache, 2019, 59(5): 659-681.
[50]	Carmine Belin A, Ran C, Edvinsson L. Calcitonin gene-related peptide (CGRP) and cluster headache[J]. Brain Sci, 2020, 10(1): 30.
[51]	Wang W, Chen J, Guo X. The role of nerve growth factor and its receptors in tumorigenesis and cancer pain[J]. Biosci Trends, 2014, 8(2): 68-74.
[52]	Tian G, Zhang G, Tan Y H. Calcitonin gene-related peptide stimulates BMP-2 expression and the differentiation of human osteoblast-like cells in vitro[J]. Acta Pharmacol Sin, 2013, 34(11): 1467-1474.
[53]	Nguyen V, Meyers C A, Yan N, et al. BMP-2-induced bone formation and neural inflammation[J]. J Orthop, 2017, 14(2): 252-256.
[54]	Pereira C T, Adams S H, Kent Lloyd K C, et al. Exploring the role of peripheral nerves in trauma-induced heterotopic ossification[J]. JBMR Plus, 2024, 9(1): ziae155.
[55]	Wang W, Gong Z, Wang K, et al. Activation of the BMP2-SMAD1-CGRP pathway in dorsal root ganglia contributes to bone cancer pain in a rat model[J]. Heliyon, 2024, 10(6): e27350.
[56]	Mantyh P. Bone cancer pain: Causes, consequences, and therapeutic opportunities[J]. Pain, 2013, 154(Suppl 1): S54-S62.
[57]	Nassini R, Materazzi S, Vriens J, et al. The ‘headache tree’ via umbellulone and TRPA1 activates the trigeminovascular system[J]. Brain, 2012, 135(Pt 2): 376-390.
[58]	Jimenez-Andrade J M, Mantyh W G, Bloom A P, et al. A phenotypically restricted set of primary afferent nerve fibers innervate the bone versus skin: Therapeutic opportunity for treating skeletal pain[J]. Bone, 2010, 46(2): 306-313.
[59]	Goadsby P J, Reuter U, Hallström Y, et al. A controlled trial of erenumab for episodic migraine[J]. N Engl J Med, 2017, 377(22): 2123-2132.
[60]	Bigal M E, Dodick D W, Rapoport A M, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: A multicentre, randomised, double-blind, placebo-controlled, phase 2b study[J]. Lancet Neurol, 2015, 14(11): 1081-1090.
[61]	Caronna E, Alpuente A, Torres-Ferrus M, et al. CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention[J]. Handb Clin Neurol, 2024, 199: 107-124.
[62]	Silberstein S D. Emerging target-based paradigms to prevent and treat migraine[J]. Clin Pharmacol Ther, 2013, 93(1): 78-85.
[63]	Hoffmann J, Goadsby P J. New agents for acute treatment of migraine: CGRP receptor antagonists, iNOS inhibitors[J]. Curr Treat Options Neurol, 2012, 14(1): 50-59.
[64]	Deen M, Correnti E, Kamm K, et al. Blocking CGRP in migraine patients - a review of pros and cons[J]. J Headache Pain, 2017, 18(1): 96.
[65]	Silberstein S, Lenz R, Xu C. Therapeutic monoclonal antibodies: What headache specialists need to know[J]. Headache, 2015, 55(8): 1171-1182.
[66]	Bigal M E, Walter S. Monoclonal antibodies for migraine: Preventing calcitonin gene-related peptide activity[J]. CNS Drugs, 2014, 28(5): 389-399.
[67]	Wang W, Wang E Q, Balthasar J P. Monoclonal antibody pharmacokinetics and pharmacodynamics[J]. Clin Pharmacol Ther, 2008, 84(5): 548-558.
[68]	Mitsuoka K, Kikutani T, Miwa Y, et al. Expression of CGRP neurotransmitter and vascular genesis marker mRNA is age-dependent in superior cervical ganglia of senescence-accelerated prone mice[J]. Neurosci Lett, 2018, 664: 144-151.
[69]	Gámez B, Rodriguez-Carballo E, Ventura F. BMP signaling in telencephalic neural cell specification and maturation[J]. Front Cell Neurosci, 2013, 7: 87.
[70]	Mazaki A I, Yamauchi K, Orita S, et al. Nerve growth factor in breast cancer cells promotes axonal growth and expression of calcitonin gene-related peptide in a rat model of spinal metastasis[J]. Anticancer Res, 2022, 42(1): 581-587.
[71]	Hongo J S, Laramee G R, Urfer R, et al. Antibody binding regions on human nerve growth factor identified by homolog- and alanine-scanning mutagenesis[J]. Hybridoma, 2000, 19(3): 215-227.
[72]	Judd N P, Winkler A E, Murillo-Sauca O, et al. ERK1/2 regulation of CD44 modulates oral cancer aggressiveness[J]. Cancer Res, 2012, 72(1): 365-374.
[73]	Jiang L, Zhou Y, Tang S, et al. Nociceptive adenosine a(2A) receptor on trigeminal nerves orchestrates CGRP release to regulate the progression of oral squamous cell carcinoma[J]. Int J Oral Sci, 2024, 16(1): 46.
[74]	van den Beuken-van Everdingen M H J, de Rijke J M, Kessels A G, et al. Prevalence of pain in patients with cancer: A systematic review of the past 40 years[J]. Ann Oncol, 2007, 18(9): 1437-1449.
[75]	Bagan J, Sarrion G, Jimenez Y. Oral cancer: Clinical features[J]. Oral Oncol, 2010, 46(6): 414-417.
[76]	Connelly S T, Schmidt B L. Evaluation of pain in patients with oral squamous cell carcinoma[J]. J Pain, 2004, 5(9): 505-510.
[77]	Mu L, Sanders I. Human tongue neuroanatomy: Nerve supply and motor endplates[J]. Clin Anat, 2010, 23(7): 777-791.
[78]	Scheff N N, Ye Y, Bhattacharya A, et al. Tumor necrosis factor alpha secreted from oral squamous cell carcinoma contributes to cancer pain and associated inflammation[J]. Pain, 2017, 158(12): 2396-2409.
[79]	McIlvried L A, Atherton M A, Horan N L, et al. Sensory neurotransmitter calcitonin gene-related peptide modulates tumor growth and lymphocyte infiltration in oral squamous cell carcinoma[J]. Adv Biol, 2022, 6(9): e2200019.
[80]	Ferrari M D, Diener H C, Ning X, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): A randomised, double-blind, placebo-controlled, phase 3b trial[J]. Lancet, 2019, 394(10203): 1030-1040.
[81]	Croop R, Goadsby P J, Stock D A, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: A randomised, phase 3, double-blind, placebo-controlled trial[J]. Lancet, 2019, 394(10200): 737-745.
[82]	Coveler A L, Mizrahi J, Eastman B, et al. Pancreas cancer-associated pain management[J]. Oncologist, 2021, 26(6): e971-e982.
[83]	Thayer S P, di Magliano M P, Heiser P W, et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis[J]. Nature, 2003, 425(6960): 851-856.
[84]	Ceyhan G O, Schäfer K H, Kerscher A G, et al. Nerve growth factor and artemin are paracrine mediators of pancreatic neuropathy in pancreatic adenocarcinoma[J]. Ann Surg, 2010, 251(5): 923-931.
[85]	Edvinsson L, Warfvinge K. Recognizing the role of CGRP and CGRP receptors in migraine and its treatment[J]. Cephalalgia, 2019, 39(3): 366-373.
[86]	Edvinsson J C A, Warfvinge K, Krause D N, et al. C-fibers may modulate adjacent Aδ-fibers through axon-axon CGRP signaling at nodes of Ranvier in the trigeminal system[J]. J Headache Pain, 2019, 20(1): 105.

Relative Articles(20)

Relative Articles

[1]	Yang LI, Wen JIANG, Rong LIU, Chaomin LIU, Longyu XU, Wenjing ZHANG. Bioinformatics-based Identification of Cuproptosis Genes Associated with Prognosis and Immune Microenvironment in Lung Cancer. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20250405
[2]	Jing FU, Jianlin PU, Zhong LI, Qiuyue MAO, Chunlan LI, Xuesong GAI. Novel Conservative Treatment Mechanisms and Clinical Translation for Female Stress Urinary Incontinence. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20251218
[3]	Tangwei MOU, Dan LIANG, Yu ZHAO, Yiqun KUANG. Research Progress on the Role of Immune Cell Dysfunction in the Occurrence and Development of Liver Failure. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20250901
[4]	Yifan LIU, Xing LUO, Tianci SONG, Zhihui YANG. Research Progress on Targeted Therapy and Resistance Mechanisms of Malignant Melanoma. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20250222
[5]	Xiaobing GUO, Xiaowen LI, Hengxi LI, Yan CAO, Ping LI. miR-212-3p Targeted Regulation of NAP1L1 Inhibits Glioma Cell Proliferation，Migration and EMT. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20241104
[6]	Xiaoli SHANG, Junxue NI, Yeying WANG, Jiao SHAN, Na BAI, Song WANG. Clinical Epidemiological Characteristics of Mycoplasma Pneumoniae and Its Correlation with Climatic Environment. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20230618
[7]	Lu LI, Yunfen TIAN. Research Progress on Intestinal Microflora and Non-alcoholic Fatty Liver Disease in Children. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20230708
[8]	Ting LI, Wei-Hua GUO. Research Progress of Glycolytic Reprogramming in Oral Squamous Cell Carcinoma. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20230611
[9]	Chenxi LI, Zhuocen ZHA, Na LI, Lin LUO, Yang YANG, Wenlin CHEN. Selection of Intensive Adjuvant Therapy for Triple-positive Breast Cancer. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20231020
[10]	Jun HE, Xuezhong GU, Yating LIN, Fan LI. Research Progress on the Mechanism of Regulatory T Cells in Tumor Microenvironment of Diffuse Large B-cell Lymphoma. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20230607
[11]	Xiaohua LU, Hongxin YUAN. The Analysis of the Correlation between BTLA，CTLA-4 Gene Polymorphisms and the Efficacy and Prognosis of TACE Combined Targeted Therapy for Liver Cancer. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20230927
[12]	Xi GUO, Xiaoqing TANG, Jie WANG, Yan WAN, Bin XU, Yu LUO. Effect of Early Interventional Palliative Treatment on Pain and Anxiety in Patients with Hepatitis-Related Liver Cancer. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20220813
[13]	Qiao LUO, Hong SHI, Shaobo WANG. Role of α7-nicotinic Acetylcholine Receptor in Occurrence，Development and Therapy of Lung Cancer. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20220226
[14]	Qi Xiao , Zhong Zhao Ming , Sun Chuan Zheng . . Journal of Kunming Medical University,
[15]	Wu Jiang , Wang Yun Hua , Yao Li Qin , Fei Yan Yan , Xie Shan , Shi Tao . . Journal of Kunming Medical University,
[16]	Zhu Zhong Shan , Yan Wen Hui , Li Xiao Bing , Yang Zhou , Bai Peng . Driver Genes Mutation and Survival Analysis in 200 Patients with Pulmonary Adenocarcinoma Brain Metastasis. Journal of Kunming Medical University,
[17]	Zhang Yi . . Journal of Kunming Medical University,
[18]	Xu Ke Dong . . Journal of Kunming Medical University,
[19]	Chen Xian Yu . . Journal of Kunming Medical University,
[20]	Yan Heng Xiang . . Journal of Kunming Medical University,